Podcasts about fda

Self Created Valuation Boosts Apple Announces new Podcast push AI – A breakdown Playing them like a fiddle – Warner Brothers PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - A NEW CTP just announced - China releasing new AI models - AI - A breakdown - we are on overload - Big Employment news.... Markets - Self Created Valuation Boosts - Apple Announces new Podcast push - Playing them like a fiddle - Warner Brothers Quick Note - Going to rip up the playbook on something this week on TDI Podcast. Anyone who owns an annuity should listen to what is about to come on next Sundays show.....  No Agenda... Olympics - Anything to discuss? MONEY FOR ALL - The average tax refund is 10.9% higher so far this season, compared to about the same point in 2025, according to early filing data from the IRS. - The 2026 tax season opened Jan. 26, and the average refund amount was $2,290 as of Feb. 6, up from $2,065 about one year prior, the IRS reported Friday night. - As of Feb. 6, the total amount refunded was more than $16.9 billion, up 1.9% compared to last year, according to the IRS release. That figure reflects current-year returns only. - This is partly because there were excess-witholdings from last year on the rules changed and paycheck withholdings were not adjusted. This is a one time situation.. Emplyment - 4.3% - "Better" than expected payrolls number - A major revision was released last Wednesday. Overall 2025 job growth was much weaker than initially reported. The total net change for the full year 2025 was revised down from +584,000 jobs to just +181,000 jobs (seasonally adjusted) — an average of only about 15,000 jobs added per month instead of ~49,000. This made 2025 one of the weakest years for job creation in recent non-recession periods. - Employment levels were consistently overstated throughout 2025 by roughly 800,000 to over 1 million jobs, peaking around mid-year. For example: By March 2025, the level was revised down by 898,000. By December 2025 (preliminary), down by 1,029,000. - Monthly changes were also adjusted downward in most cases (e.g., August's originally reported -26,000 became a larger loss of -70,000; September's +108,000 became +76,000). - The revisions reflect normal annual benchmarking, but this one was unusually large (larger than the typical 0.2% average over the prior decade), likely due to factors like overestimation of business births or other data mismatches. - In short, the data reveals that the U.S. labor market in 2025 was significantly softer than the monthly headlines suggested at the time — job growth was overstated by a substantial margin, painting a picture of a much weaker employment picture for the year. AI Updates - While U.S. markets have been focused on the impact of Anthropic and Altruist's tools on software and financial services, China's tech giants have released AI models this week that have shown advancements in robotics and video generation. - Google is reporting that China's AI models are just MONTHS behind western models - However - is this progress? In a video demo, Alibaba showed a robot with pincers for hands that appeared to be able to count oranges, pick them up and place them in a basket. It was also shown taking milk out of a fridge. - Alibaba on Monday unveiled a new artificial intelligence model Qwen 3.5 designed to execute complex tasks independently, with big improvements in performance and cost that the Chinese tech giant claims beat major U.S. rival models on several benchmarks. - Zhipu AI — which trades as Knowledge Atlas Technology in Hong Kong said the model approaches Anthropic's Claude Opus 4.5 in coding benchmarks while surpassing Google's Gemini 3 Pro on some tests. - Shares of MiniMax also jumped Thursday after it launched its updated M2.5 open-source model with enhanced AI agent tools. Grok Update - Grok, Elon Musk's AI chatbot, has been gaining ground in the U.S. over the past months, data showed, even as it draws global censure and regulatory scrutiny after being used to generate a wave of non-consensual sexualized images of women and minors. - U.S. market share of the tool rose to 17.8% last month from 14% in December, and 1.9% in January 2025, according to data from research firm Apptopia. - Men are still the largest % users of Grok ~ 78% (down from 89% in April 2025) AI Market Share - ChatGPT's share slumped to 52.9% last month from 80.9% in January last year, while Gemini's grew to 29.4% from 17.3% over the same period. AI Market Share InfoGrapic and AI Understanding - Have we gone through this? - At its core, AI is technology that lets machines perform tasks that normally require human intelligence — things like understanding language, recognizing images, making decisions, or solving problems. - Modern AI (especially since ~2022) is dominated by machine learning — systems that learn patterns from huge amounts of data instead of being explicitly programmed rule-by-rule. - Inference is the "using" or "applying" phase of AI — when a trained model takes new input and produces an output / prediction / answer. Contrast with training (the "learning" phase): ------ Training ? Like a student studying for years: very compute-heavy, expensive, done once (or rarely) on massive servers/GPUs, adjusts billions of parameters based on examples. ------ Inference ? Like the student taking a test or doing their job: much faster, cheaper, runs on your phone/laptop/cloud, uses the fixed knowledge from training to respond instantly. - gentic AI takes regular AI (like chat models) to the next level: instead of just answering questions or generating text, these systems act autonomously to achieve goals with minimal human help. "Agentic" comes from "agency" — the ability to make decisions, plan, use tools, take actions, adapt, and even learn from results — like a smart digital employee rather than just a smart answer machine. AI Infographic Last AI Item - A shortage of memory chips is hammering profits, derailing corporate plans, and inflating price tags on various products, with the crunch expected to get worse. - The fundamental reason for the squeeze is the buildout of AI data centers, with companies like Alphabet and OpenAI buying up large shares of memory chip production, leaving consumer electronics producers fighting over a dwindling supply. - The resulting price spikes are causing concern, with some warning of "RAMmageddon" and others predicting that memory chip prices will go "parabolic", bringing lavish profits to some companies but painful prices to the rest of the electronics sector. Here is something: - Gallup will no longer track presidential approval ratings after nearly 90 years - Founded by George Gallup in 1935, the Washington, DC-based management company began tracking the president's job performance 88 years ago. - Gallup told USA TODAY it will no longer publish "favorability ratings of political figures," a decision it said "reflects an evolution in how Gallup focuses its public research and thought leadership." - Gallup said the ratings are now "widely produced, aggregated and interpreted, and no longer represent an area where Gallup can make its most distinctive contribution." - "Our commitment is to long-term, methodologically sound research on issues and conditions that shape people's lives," the company wrote, adding that its work will continue through the Gallup Poll Social Series, the Gallup Quarterly Business Review, the World Poll and more. - Seems like they are unable to SHAPE opinion due to social media etc.....? Apple Podcast Update - Big news! - Apple on Monday announced that it will bring a new integrated video podcast experience to Apple Podcasts this spring. - The move comes as video viewership continues to reshape podcasting. About 37% of people over age 12 watch video podcasts monthly, according to Edison Research. - The update brings Apple Podcasts more in-line with its competitors Spotify, YouTube and now Netflix, which have increasingly leaned into video podcasting. -“Twenty years ago, Apple helped take podcasting mainstream by adding podcasts to iTunes, and more than a decade ago, we introduced the dedicated Apple Podcasts app,” said Eddy Cue, Apple's senior vice president of Services, in a statement. “ - By bringing a category-leading video experience to Apple Podcasts, we're putting creators in full control of their content and how they build their businesses, while making it easier than ever for audiences to listen to or watch podcasts.” M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo, will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Dalio Warning -  Legendary investor Ray Dalio said on Tuesday the world was “on the brink” of a capital war. - He said central banks and sovereign wealth funds were already preparing for measures like foreign exchange and capital controls. - "When money is weaponized using measures like trade embargoes, blocking access to capital markets, or using ownership of debt as leverage." - “Capital, money, matters,” Dalio said Tuesday. “We're seeing capital controls … taking place all over the world today, and who will experience that is questionable. So, we are on the brink — that doesn't mean we are in [a capital war now], but it means that it's a logical concern.” - Could this be why gold and siver are being hoarded (physical assets over digital currency? - Is China's edict to banks to diversify away from US Treasuries a sign? Self Boosted Valuation - Waymo is aiming to raise about $16 billion in a financing-round that would value it at nearly $110 billion, Bloomberg News reported, citing people familiar with the matter. - Alphabet would provide about $13 billion to the autonomous driving firm while the rest would come from investors including Sequoia Capital, DST Global and Dragoneer Investment Group, the report added. - Soooooo - Waymo is a unit of Alphabet.... Alphabet providing 80% of the funding that boosts valuations..... Hmmmmmmmm Warner Brothers -  Warner Bros Discovery Inc is considering reopening sale talks with Paramount Skydance Corp after receiving its amended offer. - The Warner Bros board is discussing whether Paramount could offer a path to a superior deal, which may ignite a second bidding war with Netflix Inc. - Paramount submitted amended terms that addressed several concerns, including covering a fee owed to Netflix and offering to backstop a Warner Bros debt refinancing. Economics Coming Up - Short Week - plenty of Reports - Wednesday - Durable Goods, Housing Starts, Industrial Production, FOMC Minutes - Thursday - Philly Fed, Initial Claims - Friday: PCE, Personal Income and Spending, GDP for Q4 (3.6%) ----- New Home Sales, UMich Feb Final   Love the Show? Then how about a Donation? ANNOUNCING THE THE CLOSEST TO THE PIN for CATERPILLAR Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

Your gray hair, thinning lashes, brain fog, and that low energy feeling after 30 might all trace back to one thing: falling NAD and stressed mitochondria. This episode breaks down what actually happens inside your cells as NAD declines, and what you can do about it using specific compounds from mushrooms, olive oil, and even chocolate. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR -Subscribe and save $15 on Wonderfeel by going to: https://getwonderfeel.com/product/wonderfeel-youngr-nmn/?utm_source=Dave&utm_medium=podcast&utm_campaign=episode2Host Dave Asprey sits down with Baran Dilaver, CEO and co-founder of Wonderfeel Biosciences, to unpack the real science behind NAD, mitochondrial energy, and long-term longevity. Baran is an entrepreneur and inventor who previously led multiple start-ups as CEO and COO, collaborated with leading scientists and medical experts, and developed award-winning products. A UC Berkeley economics graduate and former scholarship athlete, he now focuses on translating cutting-edge bioscience into practical tools that enhance people's lives. They break down how NAD powers mitochondria, why your body strategically allocates cellular energy away from peak cognitive performance as you age, and how stress accelerates that decline. You'll hear the differences between niacinamide, NR, and NMN, the FDA confusion around NMN, and why raising NAD is about cellular repair, resilience, and metabolic function, not just “more energy.” The conversation goes deep on hydroxytyrosol, the powerful olive oil polyphenol that acts as a CD38 inhibitor, and ergothioneine, a mushroom-derived antioxidant with its own receptor in the human body that can accumulate in damaged tissues. Baran shares the origin story that pushed him to research ergothioneine, along with anecdotal observations from long-term users reporting improvements in sleep, focus, energy, thicker hair, reduced gray hair, and even eyelash regrowth. You'll also hear Dave's practical take on ketosis, fasting, supplements, and metabolism, why he prefers NAD precursors over IV NAD for most people, how methyl donors affect NAD IV tolerance, and why Wonderfeelbuilt a creatine chocolate bar sweetened with allulose to stay keto-friendly and diabetic-friendly. This is biohacking grounded in mechanism, from mitochondria and neuroplasticity to anti-aging strategy and smarter supplementation. You'll Learn: • What NAD does in the body and why oral NAD itself is not effective • How niacinamide, NR, and NMN compare as NAD precursors • Why mitochondria control energy allocation, cognition, and resilience • How hydroxytyrosol may support NAD longevity through CD38 inhibition • What ergothioneine is, why it comes from mushrooms, and why the body has a receptor for it • What long-term users commonly report: better sleep, clearer thinking, stronger energy, and cosmetic shifts • Why Dave prefers supplements over NAD IVs in most cases • How allulose differs from other sweeteners and why it matters for metabolism • Why creatine supports brain energy and how heat changes absorption strategy Thank you to our sponsors! • MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order • Branch Basics | Get 15% off at https://branchbasics.com/DAVE15 with code DAVE15 • Timeline | Go to timeline.com/Dave for 20% off• OneSkin | Try OneSkin at https://www.oneskin.co/DAVE and use code DAVE for 15% off Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: NAD supplementation, NMN benefits, NR vs NMN, nicotinamide mononucleotide, mitochondrial function, CD38 inhibition, hydroxytyrosol olive oil, ergothioneine mushrooms, mushroom antioxidant benefits, Alzheimer's prevention strategies, brain fog after 30, mitochondrial energy production, anti aging supplements, longevity compounds, fertility mitochondrial health, NAD IV vs oral NMN, creatine for brain health, allulose sweetener benefits, keto friendly chocolate, GLP 1 natural support, biohacking longevity, neuroplasticity support, metabolism optimization, fasting and NAD levels, ketosis and mitochondria, supplement regulation FDA, functional medicine longevity, Dave Asprey biohacking, Wonderfeel NMN Resources: • Wonderfeel Website: https://getwonderfeel.com/product/wonderfeel-youngr-nmn/?utm_source=Dave&utm_medium=podcast&utm_campaign=episode2• Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 - Introduction 01:13 - What Is Wonderfeel 05:31 - NAD and NMN Explained 09:41 - FDA Status of NMN 13:50 - Supplements vs Pharmaceuticals 16:48 - How NAD Powers Mitochondria 25:46 - NAD Benefits and Effects 30:57 - Hydroxytyrosol 35:03 - Ergothioneine 41:55 - Alzheimer's and Brain Health 44:10 - Vitamin D and K2 46:15 - Sustainable Packaging 49:26 - Creatine Bars 51:43 - Allulose Deep Dive 59:28 - Inflammation Research 01:02:15 - Supplement Regulation See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

From FCC Chair Brendan Carr—who keeps trying to silence the political opinions of late night TV comedians, to DHS pressuring social media companies to expose anti-ICE accounts, and to the willingness of serial killer RFK, Jr and his MAHA cohort to stack up dead children so they can keep their antivax con going—it's clear the shamelessness of MAGA knows no bounds. But even if the coalition that delivered Trump's victory in ‘24 has been shattered, the Dems have to skip the seven-point policy plans and focus on the economy and Trump's corruption. And Dem candidates need to do their own tweeting. Plus, the potential legal peril for Kristi and Corey, Virginia went big and bold against Republicans on redistricting, and an homage to Jesse Jackson.Rick Wilson joins Tim Miller.show notes Will Sommer on Bannon's legal trouble with his memecoin  Jonathan on the FDA's anti-vaccine agenda Rick on how the pro-democracy coalition is winning  Colbert's banned interview with James Talarico  Abby Phillip's book on Jesse Jackson, "A Dream Deferred"  Tickets are now on sale for our LIVE shows in Dallas on March 18 and in Austin on March 19. Plus, we have a handful of seats still available for our second show in Minneapolis on February 18. TheBulwark.com/Events. Get $35 off your first box of wild-caught, sustainable seafood—delivered right to your door. Go to: https://www.wildalaskan.com/BULWARK.

Gwyneth sits down with Mike Blue—CEO of HistoSonics—to explore histotripsy, a breakthrough noninvasive ultrasound technology designed to destroy tumors without surgery, chemotherapy, or radiation. He shares the 25-year journey behind the technology, the patients already benefiting from the FDA-cleared treatment for liver tumors, and how this approach could challenge decades of invasive cancer care—signaling a profound shift toward safer, more precise treatment. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Armed with nothing more than a name and an old family photo, Lexie goes on the hunt to find her biological father.  And when she finds him she realizes she has a secret she can't share with him.  It's a complicated story of family, secrets and broken trust. DAILY LOOK For 50% off your first order, head to DailyLook.com and use code SECRETROOM. HERS Thank you, HERS! Go to forhers.com/SECRET for your personalized weight loss treatment options. Weight Loss by Hers is not available everywhere. Compounded products are not approved or reviewed for safety, effectiveness, or quality by the FDA. Prescription required. See website for full details, important safety information, and restrictions. Actual price depends on product and plan purchased. HOME CHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. WILD GRAIN Get $30 off your first box + free Croissants in every box. Go to wildgrain.com/SECRET to start your subscription. PICTURES See pictures of Lexie, her family and fiancee. They are waiting for you on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED If you are in love with Lexie, and who couldn't be at this point, she's back in one week to talk about what it was like to share her finally secret. She also tells us her max meet-cute story of how she met her fiancee.  There's a free trial for the show, after which we hope you'll stay on as a supporting member, because the Secret Room is a listener supported show.  Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See our sponsors and their offers: secretroompodcast.com/codes

Tidepool was founded in 2013, part of the incredible era of DIY diabetes progress, and has since helped change how hundreds of thousands of people with diabetes see and use their data. I'm talking to CEO Brandon Artibter about how open-source innovation became FDA-cleared technology, and what's next.. including a new partnership with Oura Ring to study sleep, activity, and menstrual cycles, and continued work with Tidepool Loop. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes with Tidepool, including the announcment of bringing Loop to the FDA back in 2018! https://diabetes-connections.com/?s=tidepool Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com 

What if robots could handle tedious retraction, precise bone milling, or even autonomous suturing, freeing surgeons to focus on complex decision-making and more patients?In this episode of the Succeed In Medicine Podcast, Dr. Bradley Block speaks with Dr. Michael Yip, as he explains that today's robots primarily serve as extensions of human surgeons via teleoperation (e.g., da Vinci for precision in hard-to-reach areas), enhancing dexterity, visualization, and accuracy rather than replacing them. He highlights existing autonomous applications in "hard tissue" procedures like the Mako or Stryker robots for precise bone milling in joint replacements, and non-contact examples like CyberKnife for focused radiation therapy.For soft tissue surgery, the more challenging domain due to tissue deformation and variability, autonomy is emerging in simpler, repetitive tasks such as retraction, suctioning, or basic suturing, with demonstrations dating back 15 years but real-world deployment lagging due to engineering, data, and economic hurdles. Dr. Yip discusses why demos in controlled settings don't easily translate to ORs, the shift to data-driven AI (with risks of out-of-distribution failures), and regulatory challenges like FDA expertise gaps and defining probabilistic safety. He predicts stepwise adoption: starting with assistant-level tasks (replacing med student/intern roles in retraction/suction), then progressing to free surgeons for higher-value work, especially in underserved rural areas via telesurgery. Full "skin-to-skin" autonomy (e.g., simple lipoma excision or appendectomy) remains years away, limited by hardware combining strength, dexterity, and precision in one system, though teams of specialized robots could accelerate progress. Ultimately, robotics will alleviate surgeon burnout from growing demand, not eliminate jobs soon.Three Actionable TakeawaysEmbrace Robotics Early in Training: Surgeons and trainees should gain hands-on experience with diverse robotic technologies now, treating them as essential tools that augment precision and dexterity rather than threats to obsolescence.Focus on Repetitive Tasks for Autonomy Gains: Prioritize robotic assistance in tedious, physically demanding steps like retraction, suctioning, or basic closure to free up time, reduce fatigue, and improve efficiency in high-volume or resource-limited settings.Stay Informed on Regulatory and Economic Shifts: Monitor evolving FDA guidelines for AI/surgical autonomy, economic incentives (e.g., cost savings in joint replacements or anastomosis), and liability frameworks to prepare for integration that enhances patient access and outcomes.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Michael Yip is an Associate Professor of Electrical and Computer Engineering at UC San Diego and Director of the Advanced Robotics and Controls Laboratory (ARCLab). His research focuses on surgical robots, biomimetic design, robot learning, autonomous robotic surgery, and deformable tissue manipulation. He has received the NSF CAREER Award, NIH Trailblazer Award, IEEE RAS Distinguished Lecturer recognition, and was named Faculty Innovator of the Year at UCSD in 2024 and elected to the National Academy of Inventors. Previously a Disney researcher at Amazon Robotics, he holds a BSc in Mechatronics Engineering from the University of Waterloo, MS in Electrical Engineering from the University of British Columbia, and PhD in Bioengineering from Stanford University.Website: yip.eng.ucsd.edu and ucsdarclab.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter   This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury's Lauren Martz assesses how the oral SERD landscape is evolving.Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy from Disc Medicine and a vaccine from Moderna, and why he is calling on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA's CSO, CMO, and director of CBER.View full story: https://www.biocentury.com/article/658455#TargetedProteinDegradation #OralSERDs #OncologyDrugDevelopment #FDASetbacks #CBER00:00 - Introduction03:12 - Oral SERD Spotlight11:40 - Setbacks at FDA15:12 - Disc Medicine CRLTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode of the IRH Clinician's Corner, guest host (and IRH lead practitioner) Sara Fields sits down with Rachel Frankenthal to do a deep dive into the evolving landscape of menopause and cancer survivorship care, unpacking the profound impact of the FDA's recent removal of the black box warning on hormone replacement therapy. Rachel shares her personal journey from the world of dance to leading-edge women's health, discusses the myths and realities around hormone therapy, and offers actionable strategies for both clinicians and women facing these issues.   In this interview, we discuss:   The historical context of hormone therapy Ongoing misconceptions and fear surrounding hormone therapy Women's Health Initiative (WHI) data and what it shows System-wide educational deficits and resultant misinformation Diet and lifestyle interventions for menopausal women and cancer survivors Early recognition and frequently ordered labs/monitoring The Clinician's Corner is brought to you by the Institute of Restorative Health. Follow us: https://www.instagram.com/instituteofrestorativehealth/   Connect with Rachel Frankenthal Website:  https://www.uclahealth.org/providers/rachel-frankenthal IG: https://www.instagram.com/rachelfrankenthal/?hl=en   Resources for women: The Menopause Society:  https://menopause.org/ The Heather Hirsch Academy: https://heatherhirschacademy.com/  ISHWISH: https://www.isswsh.org/ Jackie Piasta with Monarch Health: https://www.mymonarchhealthco.com/ Alloy and Midi Health (for telehealth options):  https://www.myalloy.com/ and https://www.joinmidi.com/ Timestamps:  00:00 Path to GYN Oncology Career 06:07 Women's Hormone Therapy Controversy 08:02 Estrogen Black Box Warning Debunked 11:49 Reframing Hormone Therapy Perspectives 15:09 Hormone Therapy Benefits and Risks 18:09 "Estrogen's Role in Breast Cancer" 21:16 BRCA, Ovarian Cancer, Hormone Risks 26:28 Advocating with Evidence and Data 29:13 Choosing Menopause-Certified Providers 31:35 Hormone Management and Heather Hirsch 35:24 Individualized Menopause Care and Education 39:44 Mediterranean Diet for Health Optimization 43:35 Prioritize Exercise for Health 46:50 Reeducating Women on Health 50:03 Ovarian Cancer: Know the Symptoms 54:01 Individualized Hormone Therapy Insights 54:51 Advances in Cancer Surveillance 58:10 "Clinician's Corner: Join & Share" Speaker bio:  Rachel Frankenthal is a board-certified and licensed Physician Associate and Menopause Society Certified Practitioner with a Masters in Public Health. She specializes in gynecologic oncology, treating women with gynecologic cancers as well as women at high risk for cancer due to genetic mutations. Rachel has a special passion for menopause and cancer survivorship care. She developed the menopause clinic for cancer survivors at UCLA and has played an integral role in developing the gyn cancer survivorship program. Rachel is a certified yoga and pilates instructor and on faculty at the Heather Hirsch Academy where she teaches a course on hormone therapy for gynecologic cancer survivors.   Keywords:  hormone therapy, menopause, Women's Health Initiative (WHI), gynecologic oncology, breast cancer, estrogen, progesterone, hormone replacement therapy, black box warning, FDA hormone guidelines, cancer survivorship, genetic mutations (BRCA), ovarian cancer, vaginal estrogen, menopause education, symptom management, cancer screening, osteoporosis, bone density, lifestyle interventions, nutrition, Mediterranean diet, exercise, strength training, protein intake, fiber intake, patient advocacy, provider directories, telehealth, lab testing Disclaimer: The views expressed in the IRH Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of the Institute of Restorative Health, LLC. The Institute of Restorative Health, LLC does not specifically endorse or approve of any of the information or opinions expressed in the IRH Clinician's Corner series. The information and opinions expressed in the IRH Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. The Institute of Restorative Health, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the IRH Clinician's Corner series. By viewing or listening to this information, you agree to hold the Institute of Restorative Health, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

I am excited to share powerful insights from the latest episode of Capitalist Culture.This time, I sat down with Seth, founder of Precision Biologics and Regenerative Revival, to explore the rapidly expanding world of regenerative medicine, entrepreneurship, and leadership. His perspective on innovation, compliance, patient outcomes, and business execution is both practical and forward-looking.Here are a few highlights from our conversation.Key Lessons and Ideas:• Regenerative Medicine as a Non-Invasive AlternativeSeth explained how regenerative medicine addresses chronic and acute pain without surgery. Rather than masking pain, these therapies signal the body to heal itself, particularly in soft tissue injuries and degenerative conditions.• Stem Cell Therapy in the United StatesThere is a common misconception that patients must travel overseas for stem cell treatments. Seth clarified that umbilical cord-derived products in the United States are ethically sourced from birthing tissue and processed under strict tissue-bank and FDA guidelines. High-quality care is available domestically.• Umbilical Cord vs Autologous Stem CellsSeth described why younger umbilical cord stem cells can be more effective than using a patient's own tissue. At the same time, he emphasized compliance and responsible education, since these therapies are not FDA-approved and must be clearly communicated as experimental.• Education as the Growth EngineA major barrier in regenerative medicine is awareness. Seth uses seminars, in-home services, and hands-on clinic support to educate patients and physicians. Precision Biologics provides not only products, but training, operational systems, and marketing strategy to help clinics succeed.• Business Discipline in MedicineMany physicians struggle not with medicine, but with business. Seth highlighted the importance of marketing, sales conversations around cash pay procedures, and compliant systems that protect patient trust while enabling scale.Industry Curiosities and Forward-Looking Themes:• Capital Flow into Regenerative MedicineThere is significant investor interest flowing into research and startups across stem cells, exosomes, peptides, and hormone replacement therapy. Seth believes we are early in a major growth cycle.• Business in a Box ModelHis upcoming venture focuses on patient access and outcomes through a scalable, systems-driven approach. The emphasis is on clear goals, measurable improvement, and consistent patient feedback.• Expansion into Telehealth and Hormone OptimizationSeth is launching a telehealth platform and expanding into peptide and hormone replacement therapy, with a focus on improving healthspan, not just lifespan.Leadership and Personal Reflections:• From Door to Door Sales to Industry BuilderSeth began selling meat door to door at 19. That early exposure to rejection and persuasion shaped his entrepreneurial edge. He believes sales is the foundation of solving higher ticket problems.• Mentorship MattersLooking back, Seth wishes he had sought mentors earlier. Today he invests heavily in mentoring younger professionals so they can avoid common mistakes and compress their learning curve.• Fulfillment Over MoneyHe shared a shift from chasing income to pursuing impact, especially as a father. Success for him now is measured by patient outcomes, provider growth, and the liveSend a textConnect with Kip on LinkedInhttps://www.linkedin.com/in/kipknippel/Watch Bite-Sized Clips on YouTubehttps://www.youtube.com/@capitalistculture/shorts

In Episode 126 Joe speaks with Sue Peschin, President and CEO of the Alliance for Aging Research, about what Alzheimer's and dementia look like in the real world and how policy determines who gets help and when.  Sue explains the mission and 40–year history of the Alliance for Aging Research and lays out the scope of the Alzheimer's crisis in plain language: who is affected, how dementia types differ, and why neuropsychiatric symptoms like agitation, psychosis, and depression are so often ignored in policy and practice. They discuss why early detection matters more than ever now that disease-modifying therapies and amyloid inhibitors exist, and why so many cases are still missed in primary care. Sue walks through new blood biomarkers, digital cognitive assessments, and how Medicare coverage, CED restrictions, and the proposed ASAP Act will shape access to testing and treatment. Joe and Sue also dig into Coverage with Evidence Development (CED) in Medicare, whether CMS is overstepping what Congress intended under Section 1801, and how restrictive coverage decisions have limited access to Alzheimer's drugs to a tiny fraction of eligible patients. Finally, they talk about caregiver burden, stigma around behavioral symptoms, and what families and clinicians can realistically do today. If you care about Alzheimer's, dementia, early detection, blood biomarkers, Medicare coverage, CED, the ASAP Act, primary care, caregiver burden, vascular dementia, and aging research, this episode connects the science with the politics and the lived experience. In This ConversationJoe and Sue cover: What the Alliance for Aging Research is and why it focuses on “gap” aging and brain health issues How many Americans are living with Alzheimer's and dementia, including younger-onset cases The difference between Alzheimer's, vascular dementia, and other dementias, and why neuropsychiatric symptoms matter Why early and accurate detection is critical, even before someone qualifies for a disease-modifying therapy New tools: blood-based biomarkers, digital assessments, PET scans, and when they are used How Medicare coverage, Coverage with Evidence Development (CED), and the ASAP Act affect access to diagnostics and treatments The tension between FDA's role on safety and effectiveness and CMS's role on cost control and coverage Timestamps (Audio platforms) 0:00 Intro and Sue's background / Alliance for Aging Research 5:30 How big is the Alzheimer's and dementia problem 10:30 Why early detection matters and why diagnoses are still missed 18:30 Neuropsychiatric symptoms, stigma, and caregiver burden 26:30 Blood biomarkers, digital tools, and primary care 33:30 The ASAP Act and Medicare coverage for biomarkers 38:30 Coverage with Evidence Development (CED) and Section 1801 45:00 How to get involved and where to find resources Key Takeaways Alzheimer's is one of several dementias, and many patients have mixed dementia (Alzheimer's plus vascular changes). Early detection is vital, not only for disease-modifying therapies, but to rule out other treatable causes and to help families plan. New blood biomarkers and digital assessments could make detection cheaper and easier, but coverage and adoption lag behind the science. Medicare's CED policy has sharply limited access to Alzheimer's therapies despite FDA approval and labeled indications. The ASAP Act aims to secure Medicare coverage for Alzheimer's blood-based biomarkers without waiting on slow guideline processes. About Our GuestSue Peschin is President and CEO of the Alliance for Aging Research, the leading nonprofit focused on advancing science, policy, and education to improve healthy aging and access to care. At the Alliance, Sue has driven national work on Alzheimer's, dementia, neuropsychiatric symptoms, Medicare policy, CED reform, and aging research, empowering older adults and caregivers to advocate for better care.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung, professor and chair at Johns Hopkins Bloomberg School of Public Health, these policy shifts are an “overdue adaptation to scientific progress.” In this special edition of The Weekly, Hartung discusses howartificial intelligence (AI) and various non-animal models such as human organoids will transform drug development and delivery, especially now that the regulatory side is catching up. The FDA Modernization Act, now making its way through Congress, codifies the FDA's stated goal of starting to move away from animal testing. And in making that announcement last year, the FDA put out a roadmap for how to do this. In May, Hartung will attend the National Biotechnology Conference in San Diego as a keynote speaker. BioSpace is a media partner of the meeting, and Managing Editor Jef Akst will also attend to moderate the executive track. The 2026 National Biotechnology Conference runs May 11–14.You can find the agenda here.

In part two of this series, Dr. Tesha Monteith and Dr. Andrew Hershey discuss appropriate treatment strategies to prevent migraines in children and adolescents. Show citation:  Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546  Show transcript:  Dr. Tesha Monteith: This is Tesha Monteith with the Neurology Minute. I'm back with Andrew Hershey, professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. This is part two of our discussion on his paper published in the New England Journal of Medicine, fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, now that we have fremanezumab approved for prevention of episodic migraine in children and adolescents, and we have a number of other devices and treatments for patients that can be used as part of FDA-approved treatment or even off-label, can you discuss an appropriate treatment paradigm to prevent migraine? Dr. Andrew Hershey: I think the first and foremost part of the paradigm is to identify the disease, so recognition that headaches are a component of the disease migraine, so you have headaches attacks due to migraine is an essential part. Many of the children, adolescents and their families are unaware that that is even what they're having, and clarifying the etiology actually goes a long way. One of my former mentors, Dr. Prensky, always said that 50% of kids get better from just seeing a child neurologist, and I think it's that clarification of the diagnosis. Second to that, you need to provide a very adequate acute treatment as well as what's probably even more essential than anything else is healthy lifestyle habits. So regular eating, drinking, sleeping, and exercise. And then finally, if the headache is causing severe disability or frequent headaches or interfering with the child's school, home or social life, the prevention medications may need to be added. And this is where the fremanezumab, or if you prefer devices, devices can be used for both the acute and preventive treatment. Dr. Tesha Monteith: Well, thank you for the summary, and congratulations again on your paper. Dr. Andrew Hershey: Thank you. Dr. Tesha Monteith: Do check out the full podcast for more details about the paper and treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.

In this timely episode of I Am Refocused Radio, host Shamiah Reed sits down with Sue Liebel, Director of State Affairs for Susan B. Anthony Pro-Life America, to unpack the escalating controversies surrounding mail-order abortion pills like mifepristone. They discuss the high complication rates (including 1 in 25 women requiring emergency room care per FDA labels), the rise of coercion cases—highlighted by Rosalie Markezich's (referred to as Rosalie Marquette in discussion) traumatic experience where her boyfriend allegedly forced her to take pills mailed from a California doctor—and Louisiana's lawsuits against out-of-state providers shielded by California's laws. Liebel addresses shield laws protecting providers, the Biden-era policy changes allowing mailing, calls for the Trump administration and FDA to reinstate in-person requirements and review updated science, congressional efforts, public support for medical oversight (7 in 10 voters), the shift to 65% of abortions being chemical, and broader concerns over women's health, coercion by abusers, and interstate conflicts exemplified by Gov. Gavin Newsom's heated response. A must-listen for insights into this public health and policy flashpoint—visit sbaprolife.org and abortiondrugfacts.org for more.Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.Subscribe now at YouTube.com/@RefocusedNetworkThank you for your time. 

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

SummaryIn this Coaches Roundtable episode, Chase and Chris answer your biggest questions about some of the most talked about health trends right now.They start by breaking down injectable peptides. What are they? Do they actually work? And are they safe? While peptides are being pushed hard online, there is very little long term research in healthy humans. Many are not FDA approved and can cost hundreds to thousands of dollars per month. Chase and Chris explain why most people should focus on sleep, strength training, nutrition, and stress management before even thinking about something like this.Next, they talk about hack squat foot placement. There is no single “best” position. Your foot placement changes which muscles are emphasized. Higher feet can target more glutes and hamstrings. Lower feet can target more quads. The best setup is the one that fits your goals and feels good on your body.They also cover ginger and turmeric shots. While these ingredients may help with inflammation, they are not magic. If your diet, stress, and sleep are out of control, a small wellness shot will not fix that. The basics still matter most.Finally, they answer several questions about creatine. They explain why weight gain from creatine is just water inside your muscles, not fat. They talk about how long it takes to work, when to take it, and whether it is safe for your kidneys. Creatine is one of the most researched supplements available and can help with strength, muscle retention, brain health, and even bone health.The big message of this episode is simple. Stop chasing trends. Master the fundamentals first.Chapters(00:00) Pink Webcam Problems and Opening Banter(02:00) What Are Injectable Peptides and Are They Worth It?(10:30) The Cost, Risks, and Lack of Research Behind Peptides(13:40) Best Foot Placement for the Hack Squat(18:45) Are Ginger and Turmeric Shots Actually Effective?(23:30) Creatine Water Weight Explained(25:00) How Long Creatine Takes to Work(27:00) Best Time to Take Creatine and How to Use It(29:00) Is Creatine Safe? Kidney Myths and Who Should Avoid It(31:30) Which Form of Creatine Should You Take?SUBMIT YOUR QUESTIONS to be answered on the show: https://forms.gle/B6bpTBDYnDcbUkeD7How to Connect with Us:Chase's Instagram: https://www.instagram.com/changing_chase/Chris' Instagram: https://www.instagram.com/conquer_fitness2021/Facebook Group: https://www.facebook.com/groups/665770984678334/Interested in 1:1 Coaching: https://conquerfitnessandnutrition.com/1on1-coachingJoin The Fit Fam Collective: https://conquerfitnessandnutrition.com/fit-fam-collective

This episode is an interview with Dr. Wouter Vaes, the Chief Science Officer of Peregrion. We discuss how accelerator mass spectrometry is being used in early clinical development for drug metabolism and pharmacokinetics. We discuss using this technology to support development of oncology agents, determining absolute bioavailability without IV toxicology work, and more. Links discussed in the show:You can contact Wouter by email: wouter.vaes@peregrion.com Connect with Peregrion on LinkedIn or their websiteSymposium on microtracer studies FDA guidance on safety testing of drug metabolitesWhite paper on human ADME data You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan's newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

In this episode, Etienne Nichols sits down with Edwin Lindsay, a seasoned MedTech operator and QARA leader, to discuss the systemic challenges facing the pediatric medical device market. Following a personal experience in a neonatal ward, Edwin highlights the stark reality that many pediatric treatments rely on adult devices adapted off-label, often leading to safety risks and clinical inefficiencies.The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose.Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation.Key Timestamps00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI.03:12 – Personal Insight: Edwin's experience in the hospital and the "Guinness philosophy" of giving back.05:30 – The danger of adhesives and adapting adult materials for newborn skin.08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up.11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents.14:50 – Off-label usage risks and the "mindset shift" required for manufacturers.18:25 – Micro-timestamp: The FDA's Humanitarian Device Exemption (HDE) and P-Sub programs.21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings.25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production.Quotes"We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay"If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin LindsayTakeawaysRegulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance.Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations.Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives).Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue.ReferencesFDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations.Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain...

NBC anchor Savannah Guthrie is again pleading for her mother's return, posting to Instagram two weeks after Nancy Guthrie vanished from her Arizona home. The FBI also says a glove found nearby appears to match one worn by a suspect seen on a doorbell video and contains DNA, with final test results expected within 24 hours.President Trump said members of the new 'Board of Peace' have pledged more than $5 billion for the Gaza strip. The money would be used toward reconstruction and humanitarian efforts for the region. This comes as Trump recently ordered a second aircraft carrier group to the Middle East, amid ongoing talks with Iran over a nuclear deal. The Board of Peace is expected to meet in DC on Thursday, where the pledges will be formally announced.Ultra-processed foods are under new scrutiny from the Trump administration. Health Secretary Robert F Kennedy Junior says the FDA will consider a petition to revoke the “Generally Recognized as Safe,” or GRAS, status of dozens of refined carbohydrates. Former FDA Commissioner David Kessler filed the petition. He argues ultra-processed foods have fueled rising rates of diabetes and heart disease.

Send a textTom hosts a live cannabis legalization news show from a soon-to-open dispensary in Pekin, giving a brief tour of the sales floor, ID check area, vault, and planned community space, and noting the shop is expected to open in about three to four weeks after a three-year licensing process. The episode covers the FDA missing a cannabinoid-related deadline while acknowledging marijuana benefits but emphasizing concerns about children; a USDA Farm Bill draft that keeps the hemp definition and does not directly address hemp-derived intoxicating products; and backlash to a New York Times editorial calling for “guardrails” after previously backing legalization, with discussion about confusion between regulated cannabis and unregulated intoxicating hemp. They also mention Ohio Governor Mike DeWine urging people to stop complaining about new adult-use restrictions and a push to ban intoxicating hemp products, while citing developments in Chicago and Missouri and arguing hemp drinks and “marijuana labeled as hemp” will face increasing regulatory and banking pressure.Guest Dr. Riley Kirk (Canna Chem), PhD in pharmaceutical sciences and co-founder of a research/education nonprofit, discusses barriers to cannabis research under Schedule I and how Schedule III could expand research by enabling write-offs and reducing hurdles. She describes her group's industry-funded work, including “Science of Smokeability,” focused on what makes smokable products high quality and safer. Kirk explains current theories around cannabinoid hyperemesis syndrome (CHS), including her survey-based study of 1,000+ people diagnosed or told they have CHS, common symptoms (notably early-morning nausea), and relief via hot showers linked to TRPV1 activation; she notes competing hypotheses such as high-potency frequent THC use, vaping, genetics, or mycotoxins.00:00 Live from the Dispensary: Show Kickoff & What's Coming Up01:12 Behind the Scenes: Sales Floor Tour, Compliance Rules & Opening Timeline02:56 FDA Missed the Deadline: Cannabis Benefits, ‘Think of the Children' & Admin Chaos05:23 Farm Bill Draft Breakdown: Hemp Definition, Total THC, and What's (Not) Changing08:16 Hemp Drinks on Borrowed Time: Enforcement, Banking Risk & Political Reality Check15:54 Quick Dispensary Walkthrough: Vault Door, Restricted Areas & Build-Out Plans18:16 Meet Dr. Riley Kirk: Why Cannabis Research Is So Hard (and How It Gets Funded)22:52 Cannabinoid Hyperemesis Syndrome (CHS): Potency, Vapes, Genetics & Competing Theories29:08 Endocannabinoid Deficiency & Media Spin: Nuance vs Clickbait Cannabis Headlines32:46 “We Need More Studies” — ECS, Nervous System & What Science Is Missing34:15 Aging, Tolerance Shifts & the Entourage Effect Explained36:21 Homegrow, Trusting Inputs & Why ‘No Flower' Medical Programs Fail39:18 Rescheduling to Schedule III: Validation, Pharma Capsules vs Flower44:39 What Research Is Next: Receptor-Level Effects & Better Strain Profiling46:47 Strain Spotlight: Gorilla Glue & Building a Flavor-Based ‘Menu'49:16 Beyond Terpenes: Flavor Chemistry, Ratio Strains & Fixing THC-Only Marketing50:59 CBD/CBG Demand, Hemp Market Changes & The Lab Testing Inflation Problem57:58 Consumer-Friendly Education: Activity-Based Recommendations & 1:1 Strains01:00:02 How CBD Works (and Why It Can Boost THC Experience) + Final Wrap & Where to Find Canna ChemSupport the showGet our newsletter: https://bit.ly/3VEn9vu

Matt Holland is Chief Operating Officer at Healio, a company that has been producing high-quality, vetted information for healthcare professionals for over 100 years. The company has focused on personalization of data as it has evolved from print to digital to AI-driven access to on-demand information. Healio AI is also transforming continuing medical education from a static activity to a dynamic, personalized experience based on real-time information gaps. Matt explains, "We're a little bit unique in this space. We're family-owned and privately held, and have been for over a hundred years. So there are a lot of companies in this market right now that are not. So for decades, the focus has really been on developing and delivering quality information to healthcare professionals through all sorts of different channels. Obviously, prior to the internet, it started with good publications and journals. We also have a series of live meetings and conferences, but the primary focus really is the Healio AI, which we launched and evolved, and have been evolving, I should say, for the past 13 years or so." "We just announced the Physician Advisory Board the other day. We just announced that physicians can get credit for CME and CV credits for their searches. And the reason why I mention that is physicians are no longer looking to necessarily read a full article or go into a deep dive on a particular topic. They're looking for an answer to a question they may have either prior to the point of care, during the point of care, or after. And we all know that their time is precious, and obviously, the issue of burnout is pretty pervasive. So, our goal is really to help make their lives simpler and improve the quality of their practice and the delivery of the care that they provide." "We are a publishing news organization, and every day we develop 50-60 pieces of content from the FDA or from conferences or new studies that were released, and that's going into our model every 24 hours. So, there's sort of a deep dive substantive piece with the peer-reviewed and the journal content. There's a recency component to it with our news that goes into it, which makes the Healio AI a little bit different and we think unique, and I think balances and then hopefully more accurately and quickly addresses the questions that healthcare professionals have."  #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Listen to the podcast here

Matt Holland is Chief Operating Officer at Healio, a company that has been producing high-quality, vetted information for healthcare professionals for over 100 years. The company has focused on personalization of data as it has evolved from print to digital to AI-driven access to on-demand information. Healio AI is also transforming continuing medical education from a static activity to a dynamic, personalized experience based on real-time information gaps. Matt explains, "We're a little bit unique in this space. We're family-owned and privately held, and have been for over a hundred years. So there are a lot of companies in this market right now that are not. So for decades, the focus has really been on developing and delivering quality information to healthcare professionals through all sorts of different channels. Obviously, prior to the internet, it started with good publications and journals. We also have a series of live meetings and conferences, but the primary focus really is the Healio AI, which we launched and evolved, and have been evolving, I should say, for the past 13 years or so." "We just announced the Physician Advisory Board the other day. We just announced that physicians can get credit for CME and CV credits for their searches. And the reason why I mention that is physicians are no longer looking to necessarily read a full article or go into a deep dive on a particular topic. They're looking for an answer to a question they may have either prior to the point of care, during the point of care, or after. And we all know that their time is precious, and obviously, the issue of burnout is pretty pervasive. So, our goal is really to help make their lives simpler and improve the quality of their practice and the delivery of the care that they provide." "We are a publishing news organization, and every day we develop 50-60 pieces of content from the FDA or from conferences or new studies that were released, and that's going into our model every 24 hours. So, there's sort of a deep dive substantive piece with the peer-reviewed and the journal content. There's a recency component to it with our news that goes into it, which makes the Healio AI a little bit different and we think unique, and I think balances and then hopefully more accurately and quickly addresses the questions that healthcare professionals have." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com Download the transcript here

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Brandon D. Ayres, MD, continues this series exploring the best practices in keratoconus management with the discussion of the recent FDA approval of Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Kenneth Beckman, MD, explains what excites him about Epioxa and how it can improve patient comfort and minimize recovery time. The two surgeons also review the role of supplemental oxygen during the procedure and review the Phase 3 pivotal trial data behind Epioxa.

The Hidden Dose, a special episode of Flavors and KnowledgePicture this: It's a chilly February afternoon in Providence, Rhode Island, and you're wheeling your cart down the bright aisles of your local grocery store. The meat section stretches out ahead—rows of chicken breasts, ground beef, pork chops, all wrapped neatly and labeled with promises of freshness.But as your hand hovers over that familiar package, a question nags at you: What's really in this? Beyond the visible cuts, there's an invisible legacy: antibiotics fed to these animals throughout their lives. You're not alone in wondering. Millions of us are asking the same thing: How does routine antibiotic use in livestock impact our health, the environment, and the terrifying rise of superbugs?Let's pull back the curtain on what's happening in farms, stores, and restaurants across the U.S.—and give you the facts to shop and eat smarter.It all begins on the farm. Most of America's meat, poultry, and dairy comes from large-scale industrial operations.For decades, antibiotics—many of the very same ones doctors prescribe to us—have been routine here. Not just to treat sick animals, but mixed into feed or water to prevent disease in those crowded conditions, and even to make animals grow faster. The downside? It supercharges antibiotic resistance. Bacteria evolve, survive drug treatment, and suddenly infections in people become much harder—or even impossible—to treat.The CDC estimates that at least 2.8 million Americans deal with antibiotic-resistant infections each year, leading to over 35,000 deaths. A huge chunk of that resistance links back to overuse in agriculture, which still accounts for roughly 70% of medically important antibiotics sold in the U.S.Things are shifting, but not always in the right direction. Recent numbers are concerning: In 2024, sales of these important antibiotics for livestock jumped 16%—the biggest yearly spike since tracking began in 2011. Total sales hit nearly 7.1 million kilograms. Swine accounted for 43%, cattle for 41%, turkeys for 11%, and chickens for only 4%. That's progress in poultry, but the overall rise points to disease outbreaks, bigger herds, and continued preventive use.Globally, experts project livestock antibiotic use could climb another 30% by 2040 if nothing changes. And this isn't just a farm problem—it's a human health crisis.Regulations have stepped in. Since 2017, the FDA has banned antibiotics used solely for growth promotion and requires vet oversight for medically important antibiotics. USDA testing ensures no antibiotic residues remain in the meat or milk you buy. But that doesn't stop routine use earlier in the animal's life, where resistance builds.Some states like California go further, limiting preventive use and making grocery chains report on suppliers. Nationally, though, usage intensity is still nearly double Europe's.Now, let's bring it home to the grocery store. Chains like Walmart, Costco, and Kroger carry both conventional and antibiotic-free options. Hunt for labels like "Raised Without Antibiotics" or "No Antibiotics Ever"—these mean no antibiotics were used (with rare exceptions, such as day-old chicks in some poultry cases). Some states, like California, go further, limiting preventive use and making grocery chains report on suppliers.USDA Organic takes it higher: It prohibits almost all antibiotics, requires third-party audits, ensures better welfare, and prohibits synthetic pesticides. Brands like Applegate, Coleman Natural, and Perdue make these easy to find. Demand is growing—antibiotic-free meat sales surged years ago, and organic sales continue to trend up. New 2026 certifications add trustworthy third-party audits to fight greenwashing.But watch out: Phrases like "No Growth-Promoting Antibiotics" can still allow preventive doses, so they don't fully tackle resistance.Read the Full Content Subscribe to the FK Newsletter Free SimVal Media, USA

Roger Stone interviews Dr. Patrick Soon-Shiong, a prominent surgeon and entrepreneur, regarding a breakthrough cancer treatment called Anktiva. Dr. Patrick explains that the drug utilizes a molecule known as IL-15, which was identified by health authorities years ago as the top potential cure for cancer due to its ability to stimulate the body's natural immune cells. Despite its efficacy in treating bladder cancer and reversing lymphopenia, a condition linked to early death, the doctor argues that bureaucratic hurdles at the FDA are preventing the drug's widespread use for other terminal illnesses. The discussion concludes with a call for presidential intervention to bypass regulatory stagnation, ensuring that American medical innovations can save lives at home rather than being led primarily by foreign nations. Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded October 31, 2025 In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property.If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening.We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape.Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney.In This Episode We Discuss:• The difference between patent prosecution and patent litigation• Why it is never too early for biotech startups to think about IP• The U.S. one-year grace period vs. Europe's stricter disclosure rules• What “Freedom to Operate” really means for commercialization• Antibody patents, CDR regions, and the doctrine of equivalents• How premature disclosure can impact global patent strategy• The real-world back-and-forth of patent office “office actions”• AI-assisted prior art search at the USPTO — opportunity or risk?• How funding cycles influence patent filing decisions• Women in biotech leadership and venture funding disparities• The most rewarding part of protecting life-changing therapiesWe also break down the USPTO's new AI pilot programs designed to modernize patent examination and discuss how artificial intelligence may impact biotech patenting over the next several years.Why This MattersIntellectual property is often the single most valuable asset in a biotech company.Strong IP strategy can unlock funding, partnerships, and market exclusivity.Weak or mistimed IP decisions can permanently limit global opportunity.For founders and scientists: timing, geography, and disclosure discipline matter more than most people realize.About Our GuestDr. Kate NevillePartner, Marshall, Gerstein & BorunPhD in Immunology, JDLinkedIn: https://www.linkedin.com/in/kate-neville-phd/Firm Bio: https://www.marshallip.com/katherine-l-neville-ph-d/Charity Highlight: Girls on the Run ChicagoAn organization building confidence and resilience in young girls through mentorship and athletic achievement.https://www.girlsontherun.org/HostsDr. Chad BriscoeBioanalytical Scientific Leaderhttps://www.linkedin.com/in/chadbriscoe/Gregory AustinDirector, Business Development | Bioanalysishttps://www.linkedin.com/in/gregoryaustin1/If you enjoyed this episode, subscribe to BioTalk Unzipped on Apple Podcasts, Spotify, or your preferred platform and share with a colleague in biotech, pharma, or life sciences innovation.

President Trump's continuous self-promotion is pushing a cult of personality in America; why Trump's FDA refuses to review clinical data behind a promising new flu vaccine; abortion bans prove deadly for pregnant patients with chronic conditions To listen to this show and other MS podcasts without ads, sign up for MS NOW Premium on Apple Podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TWiV explains the observation that filamentous virions act as non-infectious interfering particles to modulate papillomavirus infection, and transmission of monkeypox virus from fire-footed rope squirrels to sooty mangabeys. Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Positions in Rosenfeld Lab (email) FDA refuses to review Moderna flu mRNA vaccine (CIDRAP) Oz measles vaccine call, too little too late? (dw.com) Defective human papillomavirus interfering virus particles (J Virol) Fire-footed rope squirrel potential MPXV reservoir (Nature) Squirrels could be MPXV reservoir (Nature) Letters read on TWiV 1297 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Silo TV series Kathy – Ancient RNA expression profiles from the extinct woolly mammoth and Ancient host-associated microbes obtained from mammoth remains Alan – Ubik, by Philip K. Dick Vincent – Starry Messenger by Neil deGrasse Tyson Listener Pick Beth – Iceland crime fiction authors Yrsa Sigurdardottir and Ragnar Jonasson Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before European leaders. We also look at the reasons behind why the FDA rejected Moderna's new flu vaccine and how that decision could shape future clinical trials. Plus, we'll look at the what happened with U.S Olympic figure skater Illia Malinin, dubbed the "Quad God," on the ice yesterday. Tipped to win the gold, Malinin didn't end up even medaling. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

On this episode of Vitality Radio, Jared takes a closer look at the cholesterol conversation and the widespread use of statin medications through a functional health lens. Rather than relying on fear or headlines, he explores how cholesterol numbers are interpreted, the difference between risk markers and root causes, and why metabolic health, inflammation, and lifestyle factors may play a larger role in long-term heart wellness. Jared also explains concepts like absolute risk, number needed to treat (NNT), and why informed decision-making matters when evaluating any health strategy. This episode encourages listeners to ask better questions, seek clarity, and consider a comprehensive approach to cardiovascular health that includes nutrition, movement, and targeted supplementation. As always, this discussion is educational and designed to empower you with information so you can make the best decisions for your personal health journey.Products:N.O. Cardio BoostVital 5 Omega-3 + AntioxidantsNatural Factors Rx Omega-3Natural Factors BerberineSolaray BerberineVital 5 Magnesium BisglycinateAdditional Information:#563: Bad Medicine: Why Your Gallbladder Isn't Disposable & How to Thrive With or Without It #332: Cholesterol Controversy - Jared's Interview on Inside The Aisle with Niki WolfeDr. Aseem MalhotraDr. Uffe RavnskovDr. Zoë HarcombeDr. Malcolm KendrickDr. David DiamondVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Join Dr. April Jasper on The Dr. April Jasper Show for an exciting deep dive into the latest breakthrough in presbyopia management! Special guests, renowned eye care experts Dr. Josh Davidson and Dr. Marc Bloomenstein, join the conversation to discuss VIZZ (aceclidine ophthalmic solution) 1.44% — the first and only FDA-approved aceclidine-based prescription eye drop designed to improve age-related blurry near vision in adults.Discover how this innovative once-daily drop works by creating a pupil-selective “pinhole effect” for enhanced depth of focus, delivering rapid improvement in near vision within 30 minutes and lasting up to 10 hours—with no negative impact to distance vision. Learn about its advantages over previous options, key clinical trial insights from the CLARITY studies, real-world applications for patients, potential side effects, and why VIZZ represents a game-changing, nonsurgical solution for the millions affected by presbyopia.Whether you're an eye care professional or someone tired of relying on readers, this episode offers expert perspectives on bringing clearer, more convenient near vision to your patients and practice! Don't miss this timely discussion on one of the newest tools transforming presbyopia care.The most common side effects that may be experienced by using VIZZ are eye redness, eye irritation, temporary dim or dark vision and headaches.Eye care professional? Click the link below.https://www.vizz.com/ecp?utm_source=podcast&utm_medium=email&utm_campaign=feb2026&utm_id=apriljasperThis podcast is sponsored by and speakers are compensated by LENZ Therapeutics, Inc.

O balanço desta semana destaca o início da vacinação de 1,2 milhão de profissionais contra a dengue no Brasil e o alerta global da IARC sobre como infecções preveníveis, como HPV e hepatites, continuam associadas a parcela relevante dos cânceres. O episódio recapitula a resolução histórica da OMS sobre hemofilia , o combate do FDA a versões não aprovadas de medicamentos GLP-1 e os novos fluxos de urgência para o manejo do AVC na gestação. Acompanhe a síntese dos fatos que exigem maior preparo técnico e resiliência na prática médica no seu podcast diário de atualização, com curadoria médica e produzido por IA.Afya News. Informação médica confiável e atualizada no seu tempo.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/14-02-2026

Here is a podcast episode description for your episode, "The Children of Thalidomide: A Medical Tragedy," tailored for your History Ignited podcast:Episode Description:"Children of thalidomide." It's one of the most sobering lines in Billy Joel's history-spanning anthem, We Didn't Start the Fire. But what is the story behind this medical catastrophe that shook the world in the late 1950s and early 1960s?In this episode of History Ignited, we dive into the dark history of Thalidomide—a drug once marketed as a "wonder cure" for morning sickness that led to thousands of children being born with severe limb deformities and other health complications.We explore:The Global Crisis: How the drug was developed in West Germany and distributed to over 40 countries.The FDA Hero: The story of Dr. Frances Kelsey, the medical officer who stood her ground against pharmaceutical pressure to keep Thalidomide out of the United States.The Aftermath: The lasting impact on the survivors, known as "Thalidomide Babies," and how the tragedy revolutionized drug safety regulations and the way we test medicine today.Join us as we break down the history behind the lyrics and honor the resilience of those affected by this avoidable tragedy.Thanks for tuning in to History Ignited!

This episode covers: • Mic-628 Could Reset Your Body Clock and Cut Jet Lag in Half A new circadian drug candidate, Mic-628, has demonstrated the ability to shift the body's internal clock and significantly reduce jet-lag recovery time in early human studies. In controlled simulations, participants experienced faster realignment of their sleep-wake cycles and improved daytime performance compared to standard approaches like melatonin and light timing alone. Dave explains how this compound targets a core clock pathway, why eastbound travel is biologically harder than westbound, and how pharmacologic chronotherapy could become a serious performance tool for frequent travelers and shift workers. He also connects circadian alignment to obesity, insulin resistance, cardiovascular risk, and cognitive decline, outlining what this breakthrough could mean if safety data continues to hold. • Source: https://www.sciencedaily.com/news/top/ • Late-Life Depression May Signal Parkinson's or Dementia New research from Shanghai Jiao Tong University found that new-onset depression in older adults is strongly associated with increased risk of Parkinson's disease and dementia. Dave reframes this finding as a brain health signal rather than a purely psychiatric issue, explaining how inflammation, microglial activation, vascular health, and neurodegeneration intersect with mood changes. He breaks down why sudden depression in someone with no prior history may warrant deeper cognitive testing, sleep evaluation, and metabolic screening instead of simply prescribing an antidepressant and moving on. This story highlights the importance of treating mood shifts as early biological data in a longevity framework. • Source: https://www.sciencedaily.com/releases/2026/02/260210040623.htm • Speed-Training Brain Games Reduced Dementia Risk by 25 Percent The long-running NIH-funded ACTIVE trial found that a specific speed-of-processing training program reduced dementia incidence by roughly 25 percent over two decades. Unlike memory or reasoning exercises, this visual processing speed protocol produced measurable long-term protection. Dave explains why reaction time and processing speed may be core capacities tied to cognitive resilience, and how structured brain-training programs descended from this research can be treated like strength training for the mind. Instead of vague advice to “stay mentally active,” this data supports building deliberate, trackable cognitive training into a midlife longevity plan. • Sources: – NPR summary: https://www.npr.org/2026/02/09/nx-s1-5702423/modest-mental-exercise-can-reduce-risk-of-dementia-for-decades-study-finds – Psychology Today analysis: https://www.psychologytoday.com/us/blog/build-your-brain/202602/new-study-means-the-age-of-dementia-prevention-begins-now • Moderate Coffee Intake Linked to Slower Brain Aging A large analysis of roughly 130,000 participants found that moderate coffee consumption, about one to three cups daily, was associated with markers of slower brain aging and lower dementia risk. Dave explains why moderate, morning-weighted caffeine intake may align acute performance benefits with potential long-term brain protection. He breaks down the dose curve, why more is not necessarily better, and how to use coffee strategically without compromising sleep or circadian rhythm. Rather than framing caffeine as either a miracle or a villain, this study supports intelligent, personalized dosing as part of a broader brain-health stack. • Source: https://www.nature.com/articles/d41586-026-00409-y • Kratom Crackdowns and the Future of Supplement Freedom Regulators are tightening restrictions on high-potency kratom derivatives such as 7-hydroxymitragynine, with new bans and stricter warning requirements emerging at the state level. The FDA continues to treat kratom and its concentrated derivatives as unapproved drugs with opioid-like effects, while local jurisdictions are targeting specific formulations linked to adverse events. Dave breaks down how this represents a broader shift in how edge-case compounds are regulated, why supply volatility and underground markets can increase risk, and what this means for biohackers who experiment with gray-area tools. He also explains how evolving enforcement strategies could shape future access to peptides, nootropics, and other advanced compounds. • Sources: – Kansas City coverage: https://www.kshb.com/news/local-news/strong-high-weak-laws-7-oh-ban-kratom-regulation-moves-forward-in-kansas-city-missouri – Florida policy coverage: https://www.wgcu.org/health/2026-02-04/kratom-advocates-tout-its-properties-but-legislators-want-strict-warnings-about-the-herbal-supplement – Legal landscape analysis: https://www.lumalexlaw.com/2025/10/09/kratoms-legal-future-how-states-and-the-federal-government-are-responding/ – FDA background: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom All source links are provided for direct access to the original reporting and research. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on circadian biology, neurodegeneration signals, cognitive training, caffeine strategy, and supplement regulation. Host Dave Asprey connects emerging science, behavioral data, and policy shifts into practical frameworks you can use to build a resilient, adaptable health stack. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Mic-628 circadian drug, jet lag recovery science, chronotherapy biohacking, late life depression dementia risk, Parkinson's prodromal symptoms, ACTIVE trial dementia prevention, speed of processing training, brain aging coffee study, moderate caffeine longevity, kratom regulation 7-OH, supplement law biohacking, neurodegeneration early signals, cognitive performance training, circadian rhythm optimization, metabolic brain health, biohacking news Thank you to our sponsors! - Antarctica Trip | Join me in Antarctica from March 8–17, 2026. Visit https://www.insiderexpeditions.com/future and use code DAVE for $1,000 off.- TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.Resources: • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 - Introduction 0:18 - Story #1: Circadian Drug for Jet Lag 2:00 - Story #2: Depression as Early Warning Sign 3:30 - Story #3: Brain Processing Speed Training 4:56 - Story #4: Coffee and Brain Health 6:24 - Story #5: Kratom Regulation 8:21 - Weekly Roundup 9:25 - Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Alexis Allegra, and her path to motherhood is one of those stories that reminds you just how many twists and pivots this journey can take. Alexis met her person later in life and, like so many of us, thought, okay — let's go, let's start trying right away. But what followed was nearly three years of fertility treatments… chemical pregnancies… failed IVF transfers… and a whole lot of heartbreak and regrouping. In her mid-40s, when things weren't unfolding the way she'd imagined, Alexis made a brave pivot to embryo donation — a decision that ultimately led her to her healthy baby. In this episode, Ali and Alexis talk about trying to build a family on a timeline you didn't plan for, grieving the losses you don't always talk about, redefining what motherhood can look like, and staying open to a path that might be different — but just as beautiful.EPISODE SPONSORS: WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.Order "Work of ART," "Beautiful Bird" and "You Are a Work of ART," now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BERRY FERTILITYIG: @berry.fertilityThe Berry Fertility app is packed with support: dozens of injection tutorials, over 100 articles, 200 FAQs, and if you still have questions, the Berry team is literally a tap away through in-app chat.Berry has a free version, and you can try Premium free for seven days. After that, it's $12.99 a month or $99 for the year.InfertileAF listeners get 30% off an annual membership with the code INFERTILEAF when you sign up at berryfertility.com or in the Berry Fertility app.Our Sponsors:* Check out BetterHelp: https://www.betterhelp.comSupport this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

It's Friday, February 13th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus China named global ‘Puppet Master' of religious persecution At a congressional hearing on February 4, former U.S. Ambassador-at-Large for International Religious Freedom Sam Brownback asserted that China continues to aid authoritarian and communist nations worldwide in their quest to suppress religious freedom, reports International Christian Concern. Brownback explained that China is the main driver of assistance to religious persecutors throughout the world. He said, “This alliance of communist, authoritarian, [and] totalitarian regimes will literally stop at nothing to control people of faith. China is the puppet master behind all of it.” According to Bob Fu of China Aid, “The Chinese Communist Party has a powerful civilian surveillance system with hundreds of millions of face-recognition cameras. They are all over China, including all four walls of the church building and pulpits and every corner of the street.” Known as “digital authoritarianism,” China is sharing its technological surveillance programs with nations, including Iran, Russia, and Saudi Arabia, that are known for abuses of religious freedom. Psalm 23:4 says, “Even though I walk through the darkest valley, I will fear no evil, for You [God] are with me; Your rod and staff, they comfort me.” Hawley demands congressional oversight of abortion pill after FDA's safety failure Republican Senator Josh Hawley of Missouri is calling for a crackdown on the abortion kill pill, Mifepristone, saying it's time for Congress to increase oversight of the drug and reinstate what he describes as basic safety guardrails, reports Fox News. He said, "Abortions are going up every single year. What's driving that is Mifepristone. It's the chemical abortion drug that is getting mailed into every state in the country. It doesn't matter what the state laws are. It doesn't matter if your state restricts abortion, bans abortion, or bans Mifepristone. It doesn't matter. It's getting mailed into every single state without a doctor visit, many times, without even a doctor's prescription. No follow-up. It's unbelievable!" Chemical abortions now account for 63% of all U.S. abortions. Not only do 11% of women who swallow the Abortion Kill Pill have to go to the emergency room due to hemorrhaging and sever bleeding, but the FDA has not completed the study of its dangers to women which it promised. Senator Kennedy: “The Karen wing of Democrat Party wants to defund ICE!” Democrats and Republicans are still battling over the funding for the Department of Homeland Security bill as Democrats demand restrictions on Immigration and Customs Enforcement or I.C.E., reports RedState.com. But, on Fox News,  Republican Senator John Kennedy of Louisiana had a very direct message to Senate Minority Leader Chuck Schumer, a Democrat from New York, about the Democrats' demands to defund I.C.E. KENNEDY: "The Karen wing of the Democratic Party wants to defund ICE, just like they wanted to defund the police. And we know how that vampire movie turned out. The Karen wing of the Democratic Party is in control of the Democratic Party. “Even if we agreed to every one of Senator Schumer's conditions -- and I won't vote for 'em -- he couldn't deliver the Democratic votes. Because the Karen wing will punish any Democrat who votes to keep the Department of Homeland Security open." Jelly Roll's wife says backlash to his Gospel message at Grammy Awards is 'borderline demonic' As The Worldview reported on February 3rd, Jason DeFord, known as Jelly Roll, won three Grammys including one for the Best Contemporary Country album. In a February 8th episode of her podcast, Jelly Roll's wife, Alisa, claims that the backlash against her husband has been “horrific” and “borderline demonic” after the singer thanked Jesus for saving his life and encouraged others to trust Christ at the Grammy Awards, reports The Christian Post. Listen. ALISA DEFORD: “Who would have thought that my husband's speech would set the internet on fire? The problem is people are weaponizing the Bible and religion way more than they are celebrating the name of Jesus. “They're just proving why people do not want to be a Christian. Seeing all of these people online just tearing apart my husband's walk of faith makes me not want to associate with that type of Christianity. It's so horrific and it is so sad and it's borderline demonic. “I've been seeing videos where people are saying that my husband, he's a ‘performative Christian.' If I wasn't trying to walk with God, I would find you and slap you, lady, but I'm trying to turn the other cheek and be better. “In what world is it okay to ever question somebody's walk with God? All he's saying is, ‘Hey, Jesus is for everybody. Jesus does not belong to one political party. Jesus loves you and the Internet lost their minds.” Some critics claimed that Jelly Roll's words were “very MAGA,” while others accused him of using religion to try to grow his brand.  Jelly Roll credited Jesus and his “beautiful wife” with changing his life. Romans 1:16 says, “For I am not ashamed of the Gospel, because it is the power of God that brings salvation to everyone who believes.” Valentine's Day birthed through Christian martyr's death And finally, have you ever wondered why we celebrate Valentine's Day on February 14th? Well, Pastor Valentine or Valentinus was a clergyman in the Roman Empire who lived during the reign of Claudius Gothicus or Claudius II. Because the Emperor was having difficulty getting young men to volunteer to serve in the army to fight his wars, he prohibited marriage which would further hurt the conscription rate. Pastor Valentine, who celebrated God's love and Biblical love between husband and wife, secretly married Christian couples in the forest which ultimately led to his arrest and imprisonment.  While Claudius took a liking to Pastor Valentinus, the bold preacher tried to convert the Emperor which resulted in a sentence of death. In Romans 10:14, the Apostle Paul asks, "How, then, can they call on the One they have not believed in? And how can they believe in the One of whom they have not heard? And how can they hear without someone preaching to them?” Valentine was beaten with clubs and stones.  And when that failed to kill him, Valentine was beheaded on February 14, A.D. 269. And now you know the rest of the story. Pick up a copy of the excellent children's book entitled Valentine: God's Courageous Evangelist. Close And that's The Worldview on this Friday, February 13th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Today's conversation dives deep into hormone health and the myths surrounding testosterone therapy, featuring Shalin Shah, CEO of Marius Pharmaceuticals, and guided by host Chris Duffin with contributions from Anthony, our co-host. We'll explore the stigmas and misconceptions attached to testosterone treatments, the groundbreaking launch of Kaisertrex (an FDA-approved oral testosterone capsule), and why hormone diagnostics matter for both men and women. Shalin Shah shares his journey as a passionate advocate for gender equity in hormone care and discusses how lifestyle, environmental factors, and stress impact hormone levels—especially as more young people experience low testosterone.  

This episode is powered by LightpathLED, a trusted provider of professional-grade red and blue light therapy panels. As Nurse Doza shares, he's used red light therapy every day for over six years — both in his clinic and at home — and now relies on LightpathLED's dual-wavelength panel for enhanced skin health, mood support, and cellular energy production. If you're ready to invest in a panel backed by a clinician's daily use, LightpathLED is the brand Nurse Doza recommends to his patients, family, and friends.

FDA Removes Black Box Warning on Estrogen: HRT Game-Changer for Women's Health After 23 years, the FDA removed the black box warning on estrogen products—a landmark decision transforming hormone replacement therapy (HRT) for women. In this episode of the Mortar and Pestle podcast, hosts Mike De Lisio and Sebastian Dennison discuss this breakthrough with Sara Hover, Senior Director of Clinical Services at PCCA.   What You'll Learn: Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concerns The timing hypothesis: why age matters when starting hormone replacement therapy Synthetic vs. bioidentical hormones and their clinical differences Oral estrogen delivery systems and safety implications Shared decision-making between patients, prescribers, and pharmacists Why compounded HRT solutions matter for patients who don't fit commercial products Hormone testing modalities and why multiple testing methods are essential Vaginal estrogen's role in preventing UTIs and hip fractures How pharmacists can educate providers and patients on HRT safety   Topics Covered: Black box warning removal, hormone replacement therapy, bioidentical hormones, menopause management, compounding pharmacy, women's health, estrogen, patient monitoring, HRT dosing strategies   Perfect for: Compounding pharmacists, healthcare providers, and anyone seeking evidence-based information on hormone replacement therapy.   Links: Why VersaBase Cream Is Your Best Choice for Women's HRT The Vaginal Microbiome, Menopause & HRT A Personalized Approach to HRT for Perimenopausal Women Backed by Science: Anhydrous VersaBase® HRT Optimizing the Patient Experience with the Right HRT Base: Insights from the Webinar

A trans-identifying man commits one of the deadliest mass shootings in Canada's history, Ohio Republicans move to protect parents who rebuff gender identity, and the FDA zeroes in on chemical preservatives in American foods. Get the facts first with Morning Wire.- - -Ep. 2629- - -Wake up with new Morning Wire merch: https://bit.ly/4lIubt3- - -Today's Sponsors:Good Ranchers - Get $25 off your first order and save up to $500 a year when you use code WIRE at https://GoodRanchers.comZipRecruiter - Go to https://ZipRecruiter.com/WIRE to try ZipRecruiter FOR FREE.- - -Privacy Policy: https://www.dailywire.com/privacymorning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. The gang discusses why management's comments had such a profound effect on the stock. Plus, a look at Moderna after the recent FDA approval and stocks on our radar Tyler Crowe, Matt Frankel, and Jon Quast discuss: - The market's sharp reaction to Shopify's earnings - e-commerce in the era of agentic commerce - The FDA's refusal to review Moderna's new flu vaccine - Stocks on our radar Companies discussed: SHOP, AMZN, GOOG, PINS, WMT, MRNA, TREX, CROX, SAFRY Host: Tyler Crowe Guests: Matt Frankel, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

(February 12, 2026) Key takeaways from Pam Bondi's House hearing. LAPD on course to put drones in the sky as first responders. Thousands of apartments set to take over empty office buildings with new L.A. ordinance. FDA declines to review Moderna flu vaccine.See omnystudio.com/listener for privacy information.

It's Thursday, February 12th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Olympics can prompt prayer among Christian viewers (Audio of Olympic theme song) Over 3,500 athletes from 93 countries are competing at the 2026 Winter Olympics Games in Milan, Italy this month. Fourteen of these countries are on the Open Doors' World Watch List of the most oppressive places to be a Christian. Those countries include Eritrea, Nigeria, Pakistan, Iran, India, and China.  Open Doors has a message for Christian viewers of the Olympics. They said, “Use the Olympics in a potentially surprising way: to pray.  … Take a moment to think about the situation of your brothers and sisters in that country and pray for it.” You can reference the organization's prayer guide for each country through a link in our transcript today at TheWorldview.com.  Ephesians 6:18 says, “Pray at all times in the Spirit with every prayer and request, and stay alert with all perseverance and intercession for all the saints.” Canadian gunman killed 10 people at school Tragically, a transgender shooter opened fire at a Canadian school on Tuesday, reports LifeSiteNews.com. Jesse Strang, a 17-year-old male pretending to be a female while wearing a dress, reportedly killed 10 people including himself.  He also injured 25 people. It's Canada's deadliest school shooting in decades.   The shooting took place at Tumbler Ridge Secondary School in northeastern British Columbia which has fewer than 200 students enrolled in Grades 7 through 12. Chris Elston, a Canadian pro-family activist, said, “He was a young man who needed serious help for his mental health. Instead, his delusion was affirmed, and the result is murdered innocent children.” Later, Elston added, “Someone needed to tell this kid the truth and help him to be happy as a man, but it's illegal to do so. It's a criminal offense of conversion therapy. So, he never got help and he got worse. Murdered children paid the price for our politicians' stupidity and cowardice. Not even our police can call him a man. A cult has taken over our society. “ Please pray for the families suffering through this unimaginable loss. YouVersion Bible engagement up dramatically in Latin America Online Bible platforms are seeing unprecedented engagement in Latin America so far this year. This trend marks a year since the YouVersion Bible platform established a regional office in Mexico City. On January 1, nearly two million people subscribed to Bible reading plans. And the app saw over 22.2 million active users on the first Sunday of the year. This marks a 20% growth from last year. Countries with record levels of engagement include Mexico, Colombia, Argentina, and El Salvador.   Only 31% o Protestants read Bible daily In the United States, new analysis from Lifeway Research found most Protestant churchgoers don't read the Bible on a daily basis. Seventeen percent of churchgoers read the Bible at least monthly. Fourteen percent read weekly. Thirty percent read a few times a week. And only 31% read the Bible daily. However, the percentage of churchgoers who read the Bible daily or at least a few times a week is now 61%. That's up from 36% in 2007. Romans 12:2 reminds us, “Do not be conformed to this world, but be transformed by the renewing of your mind, that you may prove what is that good and acceptable and perfect will of God.” GOP to FDA: Abortion Kill Pill is hurting women U.S. Senate Republicans criticized the Food and Drug Administration on Tuesday after a closed-door briefing on the abortion kill pill. The FDA is supposed to be conducting a safety review of mifepristone, one of the drugs used in chemical abortions. Republicans are accusing the agency of dragging its feet on the study. Listen to comments from Republican Senator Josh Hawley of Missouri in an interview on Washington Watch with Tony Perkins of the Family Research Council. HAWLEY: “Tony. I just think, at this point, this study, it's vital. It should be done. I don't have any confidence that the FDA is actually going to do it. And, in the meantime, abortions in this country are increasing. There are more abortions now than when Roe was the law of the land. And that's because of this chemical abortion.” U.S. homicides down 20% The Major Cities Chiefs Association released its latest report on violent crime in the U.S. The report collects data from 67 of America's biggest police departments. Compared to 2024, reported homicides were down nearly 20% last year. And reported violent crimes are falling after a surge of reports during the COVID-era shutdowns. 130,000 new American jobs The United States added 130,000 jobs in January, according to the Bureau of Labor Statistics. Analysts expected only 55,000 jobs. It's the biggest job growth in over a year. The gains were led by healthcare, social assistance, and construction.  The unemployment rate remained slightly elevated at 4.3%. 92% of Americans like religious themes in movies & TV And finally, a new survey found most Americans are open to religious themes in movies and TV shows. The 2026 Faith & Entertainment Index found 92% of U.S. adults say faith has a role to play in modern entertainment. And 77% believe it can have broad appeal. Brooke Zaugg, executive director of the Faith & Media Initiative, said, “Religion can feel scary to talk about — like politics — so it creates the illusion that it's a small group. That makes it easy for filmmakers to oversimplify it or not give it much thought, instead of recognizing how valuable faith storytelling can be when it's done well.”  Close And that's The Worldview on this Thursday, February 12th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Apple is scaling back its plans for its AI-based health coach service. Could Apple's next AirPods Pro come with cameras in them? The iPhone 17 Pro Max has the best battery life out of a plethora of other smartphones! And Apple's Lockdown Mode helped prevent the FBI from accessing a WaPo reporter's iPhone. Apple is scaling back plans for new AI-based health coach service. Apple's next AirPods Pro will come with cameras, says leaker. Leak suggests Apple's M5 Pro and M5 Max may be the same chip. NASA changes its mind, will allow Artemis astronauts to take iPhones to the Moon. Google & Apple CEOs offer seemingly contradictory statements regarding AI partnership. New Alexa's issues are already making some users return to old Siri. New Apple-backed AI model can generate sound and speech from silent videos. iPhone 17 Pro Max has the best battery life of 35 smartphones tested. Last week on my Mac: Why E cores make Apple silicon fast. FBI couldn't get into WaPo reporter's iPhone because it had Lockdown Mode enabled. Oura's FDA lobbying benefits Apple Watch, if everyone's smart about the risks. Apple Music Replay 2026 now live, here's how to find it. Ferrari's new Jony Ive–designed EV is swathed in glass and aluminum. Applications are now open for the 2026 Swift Student Challenge -- but hurry. Apple Arcade's 'Civilization VII' is good, but falls short of greatness Picks of the Week Dan's Pick: Ponies on Peacock Leo's Pick: Moody Andy's Pick: Hourly Comic Day 2026 Jason's Pick: Curling Hosts: Leo Laporte, Andy Ihnatko, and Jason Snell Guest: Dan Moren Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: zocdoc.com/macbreak